Opus Genetics, Inc. (IRD) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Opus Genetics, Inc. stock (IRD) is currently trading at $4.75. Opus Genetics, Inc. PS ratio (Price-to-Sales) is 22.00. Analyst consensus price target for IRD is $9.54. WallStSmart rates IRD as Sell.
- IRD PE ratio analysis and historical PE chart
- IRD PS ratio (Price-to-Sales) history and trend
- IRD intrinsic value — DCF, Graham Number, EPV models
- IRD stock price prediction 2025 2026 2027 2028 2029 2030
- IRD fair value vs current price
- IRD insider transactions and insider buying
- Is IRD undervalued or overvalued?
- Opus Genetics, Inc. financial analysis — revenue, earnings, cash flow
- IRD Piotroski F-Score and Altman Z-Score
- IRD analyst price target and Smart Rating
Opus Genetics, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Opus Genetics, Inc. (IRD) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Opus Genetics, Inc. (IRD) Key Strengths (0)
Supporting Valuation Data
Opus Genetics, Inc. (IRD) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Revenue declining -10.20%, a shrinking business
Very expensive at 22.0x annual revenue
Very expensive at 20.4x book value
Small-cap company with higher risk but more growth potential
Moderate institutional interest at 39.09%
Supporting Valuation Data
Opus Genetics, Inc. (IRD) Detailed Analysis Report
Overall Assessment
This company scores 13/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 0 register as strengths (avg 0/10) while 7 fall into concern territory (avg 2.1/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (22.00), Price/Book (20.35) suggest expensive pricing. Growth concerns include Revenue Growth at -10.20%, which may limit upside. Profitability pressure is visible in Return on Equity at -242.40%, Operating Margin at -296.30%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -242.40% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -10.20% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
IRD Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
IRD's Price-to-Sales ratio of 22.00x trades at a deep discount to its historical average of 116.12x (54th percentile). The current valuation is 96% below its historical high of 514.01x set in Mar 2022, and 360% above its historical low of 4.78x in Oct 2023. Over the past 12 months, the PS ratio has expanded from ~19.6x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Opus Genetics, Inc. (IRD) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Opus Genetics, Inc. operates as a stable business with moderate growth and solid fundamentals. Revenue reached 14M with 10% decline year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Debt-to-equity ratio of 0.18 indicates a conservative balance sheet with 31M in cash.
Spending 73% of revenue (10M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 10% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -10M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Opus Genetics, Inc..
Bottom Line
Opus Genetics, Inc. offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Opus Genetics, Inc.(IRD)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Opus Genetics, Inc. (IRD) is an innovative biotechnology company specializing in gene therapies for rare retinal diseases that impact vision. Leveraging cutting-edge research and proprietary gene-editing technologies, Opus aims to fulfill significant unmet medical needs through transformative solutions that restore sight. With a dedicated focus on ocular health, the company is positioned as a frontrunner in the biotech industry, appealing to investors interested in pioneering healthcare advancements. Supported by ongoing clinical trials and strategic collaborations, Opus Genetics is well-equipped to improve patient outcomes while generating substantial value for its stakeholders.